{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["43(14)"],"submitter":["Tardif JC"],"funding":["Akcea Therapeutics"],"pubmed_abstract":["Aims
Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.Methods and results
A randomized, double-blind, placebo-controlled, dose-ranging study was conducted in 114 patients with fasting serum triglycerides 200-500 mg/dL (2.26-5.65 mmol/L). Patients received olezarsen (10 or 50 mg every 4 weeks, 15 mg every 2 weeks, or 10 mg every week) or saline placebo subcutaneously for 6-12 months. The primary endpoint was the percent change in fasting triglyceride lev"],"journal":["European heart journal"],"pagination":["1401-1412"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8986458"],"repository":["biostudies-literature"],"pubmed_title":["Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk."],"pmcid":["PMC8986458"],"pubmed_authors":["Baum SJ","Bartlett VJ","Ballantyne CM","Alexander VJ","Hurh E","Amour ES","Kingsbury J","Karwatowska-Prokopczuk E","Tami J","Witztum JL","Tsimikas S","Tardif JC","Figueroa AL","Shapiro MD","Moriarty PM","Geary RS","Gaudet D","O'Dea LSL"],"additional_accession":[]},"is_claimable":false,"name":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.","description":"Aims
Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.Methods and results
A randomized, double-blind, placebo-controlled, dose-ranging study was conducted in 114 patients with fasting serum triglycerides 200-500 mg/dL (2.26-5.65 mmol/L). Patients received olezarsen (10 or 50 mg every 4 weeks, 15 mg every 2 weeks, or 10 mg every week) or saline placebo subcutaneously for 6-12 months. The primary endpoint was the percent change in fasting triglyceride lev","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-06-07T03:21:00.338Z","creation":"2024-10-18T03:20:07.896Z"},"accession":"S-EPMC8986458","cross_references":{"pubmed":["35025993"],"doi":["10.1093/eurheartj/ehab820"]}}